Potential role of cytochrome P450-1B1 in the metabolic activation of 4-aminobiphenyl in humans

Molecular Carcinogenesis

Volumn 48, Issue 8, 2009, Pages 685-691

  Ketelslegers, Hans B ^a   Godschalk, Roger W L ^a   Eskens, Bart J M ^a   Dallinga, Jan W ^a   Gottschalk, Ralph W H ^a   Van Schooten, Frederik J ^a   Van Delft, Joost H M ^a   Kleinjans, Jos C S ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

4 ABP Hb adducts; Cigarette smoke; Genetic susceptibility; Polymorphisms

Indexed keywords

4 BIPHENYLAMINE; CYTOCHROME P450 1B1; 4-BIPHENYLAMINE; AMINOBIPHENYL DERIVATIVE; BIOLOGICAL MARKER; CARCINOGEN; CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450; HEMOGLOBIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MALE; METABOLIC ACTIVATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BIOTRANSFORMATION; DNA ADDUCT; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PHYSIOLOGY; RISK FACTOR; SMOKING;

ADULT; AMINOBIPHENYL COMPOUNDS; BIOLOGICAL MARKERS; BIOTRANSFORMATION; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMOGLOBINS; HUMANS; MALE; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING;

EID: 68849126310     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20530     Document Type: Article

References (43)

1. Smith CJ, Perfetti TA, Garg R, Hansch C. IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values. Food Chem Toxicol 2003;41:807-817. (Pubitemid 36555886)
2. Vineis P. Epidemiological models of carcinogenesis: The example of bladder cancer. Cancer Epidemiol Biomarkers Prev 1992;1:149-153.
3. Lower GM, , Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 1979;29:71-79.
4. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics 1995;5:259-274.
5. Guengerich FP, Humphreys WG, Yun CH, et al. Mechanisms of cytochrome P450 1A2-mediated formation of N-hydroxy arylamines and heterocyclic amines and their reaction with guanyl residues. Princess Takamatsu Symp 1995;23: 78-84.
6. Sim SC, Ingelman-Sundberg M. The human cytochrome P450 Allele nomenclature committee web site: Submission criteria, procedures, and objectives. Methods Mol Biol 2006;320:183-191.
7. Hammons GJ, Dooley KL, Kadlubar FF. 4-Aminobiphenyl-hemoglobin adduct formation as an index of in vivo N-oxidation by hepatic cytochrome P-450IA2. Chem Res Toxicol 1991;4:144-147.
8. Tsuneoka Y, Dalton TP, Miller ML, et al. 4-aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J Natl Cancer Inst 2003;95:1227-1237. (Pubitemid 37069553)
9. Kimura S, Kawabe M, Ward JM, et al. CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. Carcinogenesis 1999;20: 1825-1830. (Pubitemid 29410564)
10. Turesky RJ, Constable A, Richoz J, et al. Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P450 1A2. Chem Res Toxicol 1998;11:925-936. (Pubitemid 28390194)
11. Shimada T, Hayes CL, Yamazaki H, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996;56:2979-2984. (Pubitemid 26199741)
12. Harper PA, Wong JY, Lam MS, Okey AB. Polymorphisms in the human AH receptor. Chem Biol Interact 2002;141: 161-187.
13. Quattrochi LC, Vu T, Tukey RH. The human CYP1A2 gene and induction by 3-methylcholanthrene. A region of DNA that supports AH-receptor binding and promoter-specific induction. J Biol Chem 1994;269:6949-6954. (Pubitemid 24191092)
14. Tompkins LM, Wallace AD. Mechanisms of cytochrome P450 induction. J Biochem Mol Toxicol 2007;21:176-181.
15. Whitlock JP, Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999;39:103-125.
16. Zhang L, Savas U, Alexander DL, Jefcoate CR. Characterization of the mouse Cyp1B1 gene. Identification of an enhancer region that directs aryl hydrocarbon receptormediated constitutive and induced expression. J Biol Chem 1998;273:5174-5183. (Pubitemid 28108679)
17. Berwick M, Matullo G, Song YS, et al. Association between aryl hydrocarbon receptor genotype and survival in soft tissue sarcoma. J Clin Oncol 2004;22:3997-4001. (Pubitemid 41079883)
18. Yu MC, Ross RK, Chan KK, et al. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian smokers and non-smokers. Cancer Epidemiol Biomarkers Prev 1995;4: 861-864.
19. Godschalk RW, Dallinga JW, Wikman H, et al. Modulation of DNA and protein adducts in smokers by genetic polymorphisms in GSTM1, GSTT1, NAT1 and NAT2. Pharmacogenetics 2001;11:389-398. (Pubitemid 32656580)
20. Bryant MS, Skipper PL, Tannenbaum SR, Maclure M. Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers. Cancer Res 1987;47:602-608. (Pubitemid 17009633)
21. Dallinga JW, Pachen DM, Wijnhoven SW, et al. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. Cancer Epidemiol Biomarkers Prev 1998;7: 571-577.
22. Boyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 1976;5:9-15.
23. Knaapen AM, Ketelslegers HB, Gottschalk RW, et al. Simultaneous genotyping of nine polymorphisms in xenobiotic-metabolizing enzymes by multiplex PCR amplification and single base extension. Clin Chem 2004;50: 1664-1668.
24. Ketelslegers HB, Gottschalk RW, Godschalk RW, et al. Inter-individual variations in DNA adduct levels assessed by analysis of multiple genetic polymorphisms in smokers. Cancer Epidemiol Biomarkers Prev 2006;15:624-629.
25. Bryant MS, Vineis P, Skipper PL, Tannenbaum SR. Hemoglobin adducts of aromatic amines: Associations with smoking status and type of tobacco. Proc Natl Acad Sci USA 1988;85:9788-9791. (Pubitemid 19027210)
26. Georgiadis P, Demopoulos NA, Topinka J, et al. Impact of phase I or phase II enzyme polymorphisms on lymphocyte DNA adducts in subjects exposed to urban air pollution and environmental tobacco smoke. Toxicol Lett 2004;149: 269-280. (Pubitemid 38469845)
27. Bartsch H, Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996;104:569-577. (Pubitemid 26196406)
28. Vineis P. Individual susceptibility to carcinogens. Oncogene 2004;23:6477-6483.
29. Yu MC, Skipper PL, Taghizadeh K, et al. Acetylator pheno-type, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 1994;86:712-716. (Pubitemid 24138978)
30. Vineis P, Caporaso N, Tannenbaum SR, et al. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking. Cancer Res 1990;50:3002-3004. (Pubitemid 20170753)
31. Bartsch H, Caporaso N, Coda M, et al. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 1990;82:1826-1831.
32. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002;61:586-594. (Pubitemid 34171924)
33. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: Properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004;369:89-104. (Pubitemid 38161226)
34. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999;20:1607-1613. (Pubitemid 29385452)
35. Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EM. Specificity of 17beta-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica 2001;31:163-176. (Pubitemid 32635344)
36. Shimada T, Oda Y, Gillam EM, Guengerich FP, Inoue K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab Dispos 2001;29:1176-1182. (Pubitemid 32800227)
37. Abnet CC, Fagundes RB, Strickland PT, et al. The influence of genetic polymorphisms in Ahr, CYP1A1, CYP1A2, CYP1B1, GST M1, GST T1, and UGT1A1 on urine 1- hyrdoxypyrene glucuronide concentrations in healthy subjects from Rio Grande do Sul, Brazil. Carcinogenesis 2006;28:112-117.
38. Watanabe J, Shimada T, Gillam EM, et al. Association of CYP1B1 genetic polymorphismwith incidence to breast and lung cancer. Pharmacogenetics 2000;10:25-33. (Pubitemid 30142810)
39. Cecchin E, Russo A, Campagnutta E, Martella L, Toffoli G. Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a Caucasian population. Int J Biol Markers 2004;19:160-163. (Pubitemid 39106943)
40. Roos PH, Bolt HM. Cytochrome P450 interactions in human cancers: New aspects considering CYP1B1. Expert Opin Drug Metab Toxicol 2005;1:187-202.
41. Ko Y, Abel J, Harth V, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001;61:4398-4404. (Pubitemid 32685766)
42. Aklillu E, Ovrebo S, Botnen IV, Otter C, Ingelman-Sundberg M. Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. Cancer Res 2005;65:5105-5111. (Pubitemid 40827319)
43. Shimada T, Gillam EM, Oda Y, et al. Metabolism of benzo- [a]pyrene to trans-7,8-dihydroxy-7, 8-dihydrobenzo[a] pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. ChemRes Toxicol 1999;12: 623-629. (Pubitemid 29354745)